Adhd
Granules India gets US regulator FDA's approval for generic ADHD drug
Drug firm Granules India on Tuesday said its subsidiary has received approval from the US health regulator for a generic medication used to treat attention-deficit hyperactivity disorder. Granules Pharmaceuticals, Inc (GPI) has received approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Lisdexamfetamine Dimesylate chewable tablets, the drug firm said in a statement. The approved drug is available in multiple strengths; 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg, it added. The company's product is the generic equivalent to Takeda Pharmaceuticals' Vyvanse chewable tablets, the company said. The medication is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and pediatric patients aged six years and older, as well as moderate to severe binge eating disorder (BED) in adults. Lisdexamfetamine dimesylate chewable tablets are currently published on the FDA Drug Shortages List, emphasising ..
 "Granules India gets US regulator FDA's approval for generic ADHD drug")
Fahadh Faasil reveals ADHD diagnosis at 41: How does it affect adults?
Actor Fahadh Faasil said that he was clinically diagnosed with attention deficit/ hyperactivity disorder (ADHD) at the age of 41
 "Fahadh Faasil reveals ADHD diagnosis at 41: How does it affect adults?")
New study challenges adult-onset of ADHD
The new study, while smaller, mined more extensive medical histories than earlier work and found that most apparent cases of adult-onset ADHD are likely the result of substance abuse or mood problems
 "New study challenges adult-onset of ADHD")
Fast food during pregnancy could increase ADHD risk in kids
Early onset conduct problems tend to occur in tandem and can also be traced back to very similar prenatal experiences such as maternal distress or poor nutrition
 "Fast food during pregnancy could increase ADHD risk in kids")
